- Home
- / Asterion
Asterion
Asterion Summary
Company Summary
- Overview
- Asterion is a company specializing in protein engineering. It offers BIOBETTER drugs for patients with chronic, debilitating diseases. The company has a portfolio of third generation therapeutic products including growth hormone (GH) agonists (for treating growth disorders), GH antagonists (for treating acromegaly), AFT erythropoietin, AFT granulocyte colony stimulating factor.
- Type
- Private
- Status
- Active
- Founded
- 2005
- HQ
- Sheffield, GB | view all locations
- Website
- https://www.asterion.co.uk/
- Cybersecurity rating
Table of Contents
Key People
Peter Grant, Non-Executive Director
Peter Artymiuk, Founding Scientist and Head of Molecular Design
Jon Sayers, Founding Scientist and Head of Biotechnology
LocationsView all
1 location detected
Sheffield, England HQ
United Kingdom
The Innovation Centre, 217 Portobello, Broomhall
Asterion Financials
Summary Financials
- Net income (FY, 2022)
- (£116.3K)
- Cash (FY, 2022)
- £112.5K
- EBIT (FY, 2022)
- (£44.5K)
Footer menu
Product
- Intelligence Suite
- Supplier Intelligence Platform
- Craft Intelligence Portal
- Craft API
- Craft for Teams
- Supplier Intelligence Platform
- Craft Alerts
- Craft N-Tier Mapping
- Craft Risk Hub
- Chrome extension
Resources
© Craft.co 2026